---
id: "quote-beijing-boston"
type: "quote"
source_timestamps: ["§ The Rise of Chinese Competition", "¶5"]
tags: ["geopolitics", "pharma-industry"]
related: ["concept-china-pharma-ascendance", "claim-chinese-trials-efficiency"]
speaker: "Authors"
speakers: ["Anaeze C. Offodile II", "Kushal T. Kadakia", "Yashodhara Dash", "Whitney Snider", "Joseph C. Wu", "Selwyn M. Vickers"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Beijing vs. Boston for Blockbusters

> "Consequently, pharmaceutical companies searching for their next blockbuster are now as likely to fly to Beijing as they are to Boston."

The line dramatizes the geographic shift in pharmaceutical investment driven by China's rapid, cost-effective clinical-trial infrastructure — see [[concept-china-pharma-ascendance]] and the underlying [[claim-chinese-trials-efficiency]]. Attributed to the article's authors collectively.